The use of ferromagnetic nanoparticles for hyperthermia and thermoablation therapies has shown great promise in the field of nanobiomedicine. Even local hyperthermia offers numerous advantages as a novel cancer therapy; however, it requires a remarkably high heating power of more than 1 kW g−1 for heat agents. As a candidate for high heat generation, we focus on ferromagnetic nanoparticles and compare their physical properties with those of superparamagnetic substances. Numerical simulations for ideal single-domain ferromagnetic nanoparticles with cubic and uniaxial magnetic symmetries were carried out and MH curves together with minor loops were obtained. From the simulation, the efficient use of an alternating magnetic field (AMF) having a limited amplitude was discussed. Co-ferrite nanoparticles with various magnitudes of coercive force were produced by co-precipitation and a hydrothermal process. A maximum specific loss power of 420 W g−1 was obtained using an AMF at 117 kHz with H 0 = 51.4 kA m−1 (640 Oe). The relaxation behaviour in the ferromagnetic state below the superparamagnetic blocking temperature was examined by Mössbauer spectroscopy.

No abstract

Heating characteristics of Fe oxide nanoparticles designed for hyperthermia were examined. Samples with coercive forces from 50 to 280 Oe(codoped magnetite) were produced with a coprecipitation technique following by hydrothermal reaction. The maximum specific loss powers (SLPs) of 420 W/g was obtained at 117 kHz (640 Oe) for a dispersant sample with coercive force of 280 Oe (ATH9D). SLPs measured on dry powder samples at 17 kHz and measured at 117 kHz on dispersant samples were compared. The measured SLP amplitudes are lower for 17 kHz and higher for 117 kHz than those expected from ferromagnetic dc minor loops. For the 117 kHz case, friction of particles in a carrier fluid (similar mechanism to Brown relaxation in superparamagnetic dispersant samples) is considered to contribute to the heating mechanism.

Magnetic nanoparticles have recently been widely applied in the bio-medical field. Responding to the demand for a simple and sensitive magnetic assay system for bio-liquid samples, we employed a general-purpose superconducting quantum interference device (SQUID) magnetometer. Strips of filter paper were used as a liquid-specimen sample holder possessing a very small magnetic background signal. An aqueous solution of superparamagnetic iron-oxide nanoparticles (Resovist) was dropped in a tiny blot-like spot in the middle of the filter paper and the magnetization was measured. Magnetic moments of a dilution series of Resovist solutions versus the number of particles provided a linear graph, revealing that the magnetic moment per Resovist particle was 8.25 x 10(-17) emu. 1 x 10(5) cancer cells were incubated with Resovist, and the number of Resovist particles attached to the cell surface and surrounding a living cell was calculated to be 1.02 +/- 0.14 x 10(7) particles/cell. Our system using a commercial SQUID magnetometer should be more than enough to determine the number of magnetic nanoparticles biologically reacting with living cells, contributing to the application of magneto nanomaterials to the life-science field.

Even with current promising antitumor antibodies, their antitumor effects on stroma‐rich solid cancers have been insufficient. We used mild hyperthermia with the intent of improving drug delivery by breaking the stromal barrier. Here, we provide preclinical evidence of cetuximab + mild hyperthermia therapy. We used four in vivo pancreatic cancer xenograft mouse models with different stroma amounts (scarce, MIAPaCa‐2; moderate, BxPC‐3; and abundant, Capan‐1 and Ope‐xeno). Cetuximab (1 mg/kg) was given systemically, and the mouse leg tumors were concurrently heated using a water bath method for 30 min at three different temperatures, 25°C (control), 37°C (intra‐abdominal organ level), or 41°C (mild hyperthermia) (n = 4, each group). The evaluated variables were the antitumor effects, represented by tumor volume, and in vivo cetuximab accumulation, indirectly quantified by the immunohistochemical fluorescence intensity value/cell using antibodies against human IgG Fc. At 25°C, the antitumor effects were sufficient, with a cetuximab accumulation value (florescence intensity/cell) of 1632, in the MIAPaCa‐2 model, moderate (1063) in the BxPC‐3 model, and negative in the Capan‐1 and Ope‐xeno models (760, 461). By applying 37°C or 41°C heat, antitumor effects were enhanced shown in decreased tumor volumes. These enhanced effects were accompanied by boosted cetuximab accumulation, which increased by 2.8‐fold (2980, 3015) in the BxPC‐3 model, 2.5‐ or 4.8‐fold (1881, 3615) in the Capan‐1 model, and 3.2‐ or 4.2‐fold (1469, 1922) in the Ope‐xeno model, respectively. Cetuximab was effective in treating even stroma‐rich and k‐ras mutant pancreatic cancer mouse models when the drug delivery was improved by combination with mild hyperthermia.